Biomarkers for assessing predisposition to severe covid-19 risk for mitigating severity and treatment strategies
MYPI2024007353A0Pending Publication Date: 2026-06-19UNIVERSITI MALAYA
0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2024007353
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-12-19
- Publication Date
- 2026-06-19
Abstract
BIOMARKERS FOR ASSESSING PREDISPOSITION TO SEVERE COVID-19 RISK FOR MITIGATING SEVERITY AND TREATMENT STRATEGIES ABSTRACT The present invention discloses an in vitro method (10) for predicting and determining the severity of COVID-19 in COVID-19 patients, comprising the steps of: collecting whole blood samples from COVID-19 patients (11); extracting DNA from the whole blood samples (12); using Ion AmpliSeq NGS panels to target specific genes associated with inflammatory and immune responses (13); and sequencing the DNA to identify five genetic variants (14). The five genetic variants identified in the present invention are: HLA-C, chr6:31239116 (1); IFNL3, chr19:39734325 (2); SLC6A4, chr17:28530193 (3); MUC5B, chr11:1264742 (4); and MUC5B, chr11:1267627 (5). The method (10) provides a more precise assessment of an individual's risk of developing severe COVID-19, enabling early diagnosis and personalized treatment strategies. Most illustrated figure: Figure 3
Need to check novelty before this filing date? Find Prior Art
